Education
About Us
Working with TipRanks
Follow Us
Cyfuse Biomedical K.K. (JP:4892)
:4892
Total Valuation
Cyfuse Biomedical K.K. has a market cap or net worth of ¥6.80B. The enterprise value is ¥5.87B.
Market Cap¥6.80B
Enterprise Value¥5.87B
Share Statistics
Cyfuse Biomedical K.K. has 8,373,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,373,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cyfuse Biomedical K.K.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -26.48%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-26.48%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee2.59M
Profits Per Employee-41.54M
Employee Count21
Asset Turnover0.02
Inventory Turnover0.68
Valuation Ratios
The current PE Ratio of Cyfuse Biomedical K.K. is -4.17. Cyfuse Biomedical K.K.’s PEG ratio is 0.44.
PE Ratio-4.17
PS Ratio0.00
PB Ratio3.11
Price to Fair Value1.43
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.44
Income Statement
In the last 12 months, Cyfuse Biomedical K.K. had revenue of 54.45M and earned -872.24M in profits. Earnings per share was -108.31.
Revenue54.45M
Gross Profit16.45M
Operating Income-896.13M
Pretax Income-869.75M
Net Income-872.24M
EBITDA-824.22M
Earnings Per Share (EPS)-108.31
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Cyfuse Biomedical K.K. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change-0.96%
50-Day Moving Average926.54
200-Day Moving Average735.25
Relative Strength Index (RSI)27.09
Average Volume (3m)122.43K
Important Dates
Cyfuse Biomedical K.K. upcoming earnings date is Aug 19, 2025, TBA (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Cyfuse Biomedical K.K. as a current ratio of 5.00, with Debt / Equity ratio of 33.52%
Current Ratio5.00
Quick Ratio4.91
Debt to Market Cap0.23
Net Debt to EBITDA2.67
Interest Coverage Ratio-94.19
Taxes
In the past 12 months, Cyfuse Biomedical K.K. has paid 2.49M in taxes.
Income Tax2.49M
Effective Tax Rate>-0.01
Enterprise Valuation
Cyfuse Biomedical K.K. EV to EBITDA ratio is -1.75, with an EV/FCF ratio of -1.87.
EV to Sales26.43
EV to EBITDA-1.75
EV to Free Cash Flow-1.87
EV to Operating Cash Flow-1.89
Balance Sheet
Cyfuse Biomedical K.K. has ¥3.05B in cash and marketable securities with ¥852.00M in debt, giving a net cash position of -¥2.20B billion.
Cash & Marketable Securities¥3.05B
Total Debt¥852.00M
Net Cash-¥2.20B
Net Cash Per Share-¥262.73
Tangible Book Value Per Share¥315.28
Margins
Gross margin is 13.45%, with operating margin of -1645.91%, and net profit margin of -1602.02%.
Gross Margin13.45%
Operating Margin-1645.91%
Pretax Margin-1597.45%
Net Profit Margin-1602.02%
EBITDA Margin-1513.82%
EBIT Margin-1579.97%
Analyst Forecast
The average price target for Cyfuse Biomedical K.K. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast4.83%
EPS Growth Forecast-21.44%